Related Experiment Video
Updated: Mar 28, 2026

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice
Miki Nishio1, Keishi Sugimachi2, Hiroki Goto1
1Medical Institute of Bioregulation, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka 819-0395, Japan;
Abstract:
Mps One Binder Kinase Activator (MOB)1A/1B are core components of the Hippo pathway that coactivate large tumor suppressor homolog (LATS) kinases. Mob1a/1b double deficiency in mouse liver (LMob1DKO) results in hyperplasia of oval cells and immature cholangiocytes accompanied by inflammatory cell infiltration and fibrosis. More than half of mutant mice die within 3 wk of birth. All survivors eventually develop liver cancers, particularly combined hepatocellular and cholangiocarcinomas (cHC-CCs) and intrahepatic cholangiocellular carcinomas (ICCs), and die by age 60 wk. Because this phenotype is the most severe among mutant mice lacking a Hippo signaling component, MOB1A/1B constitute the critical hub of Hippo signaling in mammalian liver. LMob1DKO liver cells show hyperproliferation, increased cell saturation density, hepatocyte dedifferentiation, enhanced epithelial-mesenchymal transition and cell migration, and elevated transforming growth factor beta(TGF-β)2/3 production. These changes are strongly dependent on Yes-Associated Protein-1 (Yap1) and partially dependent on PDZ-binding motif (Taz) and Tgfbr2, but independent of connective tissue growth factor (Ctgf). In human liver cancers, YAP1 activation is frequent in cHC-CCs and ICCs and correlates with SMAD family member 2 activation. Drug screening revealed that antiparasitic macrocyclic lactones inhibit YAP1 activation in vitro and in vivo. Targeting YAP1/TAZ with these drugs in combination with inhibition of the TGF-β pathway may be effective treatment for cHC-CCs and ICCs.
Insights
Mps One Binder Kinase Activator (MOB)1A/1B deficiency in mouse liver causes severe liver cancer. Targeting YAP1/TAZ and TGF-β pathways with macrocyclic lactones shows potential for treating human liver cancers.
Area of Science:
- Cell Biology
- Oncology
- Molecular Biology
Background:
- Mps One Binder Kinase Activator (MOB)1A/1B are essential Hippo pathway components that coactivate large tumor suppressor homolog (LATS) kinases.
- Liver-specific double deficiency of Mob1a/1b (LMob1DKO) in mice leads to severe liver pathologies, including hyperplasia and mortality.
- This phenotype represents the most severe observed among mutations in Hippo signaling components, highlighting MOB1A/1B's critical role in mammalian liver Hippo signaling.
Purpose of the Study:
- To investigate the role of MOB1A/1B in liver homeostasis and tumorigenesis.
- To elucidate the molecular mechanisms underlying liver cancer development in LMob1DKO mice.
- To identify potential therapeutic targets for liver cancers driven by Hippo pathway dysregulation.
Main Methods:
- Generation of liver-specific Mob1a/1b double knockout (LMob1DKO) mice.
- Histopathological analysis of liver tissues to assess cellular changes and tumor development.
- Molecular analysis to determine the involvement of key signaling pathways, including YAP1, TAZ, and TGF-β.
- In vitro and in vivo drug screening for potential therapeutic agents.
Main Results:
- LMob1DKO mice exhibit hyperplasia, inflammation, fibrosis, and develop combined hepatocellular and cholangiocarcinomas (cHC-CCs) and intrahepatic cholangiocellular carcinomas (ICCs).
- Liver cells in LMob1DKO mice display hyperproliferation, dedifferentiation, enhanced epithelial-mesenchymal transition, and increased TGF-β2/3 production.
- The observed phenotype is critically dependent on Yes-Associated Protein-1 (Yap1) and partially on PDZ-binding motif (Taz) and Tgfbr2.
- Antiparasitic macrocyclic lactones were identified as inhibitors of YAP1 activation in vitro and in vivo.
Conclusions:
- MOB1A/1B are indispensable for maintaining liver homeostasis and preventing tumorigenesis.
- YAP1 activation is a key driver of liver cancer in the context of MOB1A/1B deficiency.
- Macrocyclic lactones targeting YAP1/TAZ, potentially combined with TGF-β pathway inhibition, represent a promising therapeutic strategy for cHC-CCs and ICCs.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
TGF - β Signaling Pathway
Hedgehog Signaling Pathway
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Regulation of Angiogenesis and Blood Supply